

One-pot synthesis of 4,5-dihydro-1*H*-pyrrol-3-carboxamide derivatives via a four-component reaction

Abdolali Alizadeh ^{a,*}, Atieh Rezvanian ^a, Long-Guan Zhu ^b

^a Department of Chemistry, Tarbiat Modares University, PO Box 14115-175, Tehran, Iran

^b Chemistry Department, Zhejiang University, Hangzhou 310027, PR China

Received 7 August 2007; received in revised form 10 October 2007; accepted 26 October 2007

Available online 1 November 2007

Abstract

An effective route to functionalized 4,5-dihydro-1*H*-pyrrol-3-carboxamide derivatives is described. This involves reaction of *N*-alkyl-3-oxobutanamides, which result from the addition of an amine to the diketene, and a primary amine in the presence of dibenzoylacetylene. The 1,3-dicarbonyl compounds obtained from the addition of an amine to diketene were trapped with a primary amine to produce (Z)-3-(alkylamino)-*N*¹-alkyl-2-butanamide, which reacts with dibenzoylacetylene to produce 4,5-dihydro-1*H*-pyrrol-3-carboxamide derivatives.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: Dibenzoylacetylene; Diketene; Primary amine; 4,5-Dihydro-1*H*-pyrrol-3-carboxamide; Multicomponent reaction

1. Introduction

The syntheses of pyrroles are by all means an attractive area in heterocyclic chemistry,¹ due primarily to the fact that many pyrroles are subunits of natural products² and some are the building blocks for porphyrin synthesis.³ In particular, 3,4-disubstituted 1*H*-pyrroles have generated considerable interest owing to their remarkable diversity of biological activity.⁴ A number of these compounds have been shown to possess anti-diabetic,^{5a} fungicidal,^{5b} or antibacterial^{5c} properties.

Pyrrole derivatives, especially the methyl homologs, are found in coal tar and bone oil. The biological importance of pyrrole and its derivatives cannot be overemphasized, because several natural pigments, such as heme, chlorophyll, bile pigments, or enzymes like the various cytochromes, include the pyrrole nucleus. Many alkaloids and at least two amino acids, namely, proline and hydroxyproline, also contain the reduced pyrrole ring (pyrrolidine).

However, it is also noteworthy that the 3,4-disubstituted pyrrole system is probably the most difficult to be prepared since most electrophilic aromatic substitution reactions as

well as lithiation reactions of pyrrole rings occur predominantly at the α -position.⁶ Selective substitutions at one or more of the β -positions have been generally believed to be a challenging goal in many synthetic programs. In the literature, several approaches to 3,4-disubstituted pyrroles have been recorded,⁷ but it appears that they are less versatile for the realization of more elaborate substitution patterns.

In the context of our ongoing studies on heterocyclic construction mediated by enaminone intermediates,^{8,9} the possibility of trapping the intermediate formed between two same or different amines and diketene with dibenzoylacetylene appeared attractive from the viewpoint of devising a novel MCR.


We wish to report a simple one-pot four-component reaction between two amines and diketene in the presence of dibenzoylacetylene leading to 4,5-dihydro-1*H*-pyrrol-3-carboxamide derivatives **3** (Scheme 1).

2. Results and discussion

The reaction proceeded via a smooth 1:1:1:1 addition in dichloromethane at ambient temperature, to produce 4,5-dihydro-1*H*-pyrrol-3-carboxamide derivatives **3** in 85–95% yields (Scheme 1).

* Corresponding author. Tel.: +92 21 88006631; fax: +98 21 88006544.

E-mail address: aalizadeh@modares.ac.ir (A. Alizadeh).




3	R	R'	%Yield of 3
a	<i>n</i> -pr	<i>i</i> -Bu	95
b	<i>i</i> -Bu	<i>n</i> -pr	90
c	<i>i</i> -pr	<i>i</i> -Bu	95
d	<i>i</i> -Bu	<i>i</i> -pr	90
e	<i>i</i> -Bu	<i>i</i> -Bu	90
f	<i>n</i> -pr	<i>n</i> -pr	85
g	<i>t</i> -Bu	<i>i</i> -Bu	90
h	<i>t</i> -Bu	<i>n</i> -pr	90

Scheme 1.

The structure of compounds **3a–h** was deduced from their elemental analysis, IR, high-field ^1H , and ^{13}C NMR spectra. Compound **3b** was further elucidated by a single crystal X-ray diffraction analysis. The molecular structure of **3b** is shown in Figure 1.

Although the mechanism of the reaction between dibenzoylacetylene and (Z)-3-(alkylamino)- N^1 -alkyl-2-butenamide **5**, which was derived from the reaction of two amines with diketene, has not yet been established in an experimental manner, a possible explanation is proposed in Scheme 2. It is reasonable to assume that **3** results from initial addition of an amine to diketene,¹⁰ which leads to *N*-alkyl-3-oxobutanamide **4** and subsequent reaction of the 1:1 adduct by the another primary amine produces (Z)-3-(alkylamino)- N^1 -alkyl-2-butenamide **5**. Then, dibenzoylacetylene might be attacked by the (Z)-3-(alkylamino)- N^1 -alkyl-2-butenamide **5** to form intermediate **6**.



Scheme 2.

6, which in turn is converted to intermediate **7**. Cyclization of the intermediate **7** leads to compound **3** (see Scheme 2).

3. Conclusion

In summary, the reaction between two primary amines and diketene in the presence of dibenzoylacetylene provides a simple one-pot entry into the synthesis of 4,5-dihydro-1*H*-pyrrol-3-carboxamide derivatives of potential synthetic and pharmaceutical interest. The present method carries the advantage of being performed under the neutral conditions and requiring no activation or modification of the educts. The simplicity of the present procedure makes it an interesting alternative to complex multistep approaches.¹¹

4. Experimental

4.1. General

Melting points were measured on an Electrothermal 9100 apparatus. Elemental analyses for C, H, and N were performed using a Heraeus CHN-O-Rapid analyzer. IR spectra were recorded on a Shimadzu IR-460 spectrometer. Mass spectra were recorded on a FINNIGAN-MAT 8430 mass spectrometer operating at an ionization potential of 70 eV. ^1H and ^{13}C NMR spectra were recorded at 500.1 and 125.7 MHz, respectively, on a BRUKER DRX 500-AVANCE FT-NMR instrument with CDCl_3 as solvent. The reagents and solvents used in this work were obtained from Fluka (Buchs, Switzerland) and used without further purification. Dibenzoylacetylene was prepared according to a published procedure.^{12,13}

4.2. General procedure for the preparation of compounds **3a–h**, exemplified on **3a**

To a magnetically stirred solution of *n*-propylamine (0.059 g, 1 mmol) and diketene (0.084 g, 1 mmol) in 5 mL dry CH_2Cl_2 for 2 h was added isobutylamine (0.073 g, 1 mmol), finally after 2 h was added dropwise a solution of dibenzoylacetylene (0.23 g, 1 mmol) in 3 mL dry CH_2Cl_2 at room temperature over 10 min. The reaction mixture was allowed to stir for 2 h.




Figure 1.

The solvent was removed under reduced pressure, and the residue was recrystallized from methanol.

4.2.1. 5-Hydroxy-1-isobutyl-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-*N*³-propyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (3a)

Orange crystals (0.41 g, 95%), mp 178–180 °C. Found: C, 74.63; H, 7.32; N, 6.17%; C₂₇H₃₂N₂O₃ requires C, 74.97; H, 7.46; N, 6.48%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3235 (OH), 3045 (NH), 1605 (COPh), 1550 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.78 (3H, d, ³*J*_{HH}=6.3 Hz, CH₃CH), 0.79 (3H, d, ³*J*_{HH}=6.3 Hz, CH₃CH), 1.00 (3H, br, CH₃CH₂), 1.63–1.64 (2H, m, CH₃CH₂), 1.84 (1H, br, CH), 2.45 (3H, s, CH₃), 2.91 (1H, dd, ²*J*_{HH}=14.4 Hz, ³*J*_{HH}=6.9 Hz, CHCH₂), 3.13 (1H, dd, ²*J*_{HH}=13.8 Hz, ³*J*_{HH}=8.2 Hz, CHCH₂), 3.38–3.43 (2H, m, CH₂NH), 5.74 (1H, s, NH), 6.73 (1H, s, C=CH), 7.23–7.71 (10H, 5CH of Ph), 9.41 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =11.59 (CH₂CH₃), 14.29 (C=CCH₃), 20.14 (CHCH₃), 20.35 (CHCH₃), 23.16 (CH₃CH₂), 28.23 (CH), 41.25 (CH₂NH), 50.10 (CHCH₃), 97.07 (C–OH), 102.10 (C=CCONH), 106.62 (C=CCOPh), 125.70 (2CH of Ph), 127.84 (4CH of Ph), 128.18 (2CH of Ph), 128.42 (CH of Ph), 131.60 (CH of Ph), 139.57 (C_{ipso} of Ph), 139.80 (C_{ipso}–CO), 165.09 (C=CCH₃), 169.44 (C=CCOPh), 169.71 (CONH), 189.61 (COPh). MS, *m/z* (%): 432 (M⁺, 12), 375 (4), 346 (100), 313 (18), 254 (16), 242 (19), 105 (78), 77 (37), 57 (18), 43 (16).

4.2.2. 5-Hydroxy-*N*³-isobutyl-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-1-propyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (3b)

Orange crystals (0.39 g, 90%), mp 172–174 °C. Found: C, 74.56; H, 7.63; N, 6.29%; C₂₇H₃₂N₂O₃ requires C, 74.97; H, 7.46; N, 6.48%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3235 (OH), 3045 (NH), 1605 (COPh), 1550 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.75 (3H, br, CH₃CH₂), 1.00 (6H, d, ³*J*_{HH}=4.2 Hz, Me₂CH), 1.47 (1H, br, CH₃CH₂), 1.63 (1H, br, CH₃CH₂), 1.88 (1H, br, CH), 2.45 (3H, s, CH₃), 3.12 (1H, br, CHCH₂), 3.23 (1H, br, CHCH₂), 3.25–3.31 (2H, m, CH₂NH), 5.75 (1H, s, NH), 6.76 (1H, s, C=CH), 7.25–7.72 (10H, 5CH of Ph), 9.41 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =11.35 (CH₂CH₃), 13.79 (C=CCH₃), 20.32 (CHCH₃), 23.05 (CH₃CH₂), 28.72 (CH), 44.08 (CH₂NH), 46.92 (CH₂N), 96.54 (C–OH), 102.17 (C=CCONH), 106.33 (C=CCOPh), 125.60 (2CH of Ph), 127.85 (2CH of Ph), 127.89 (2CH of Ph), 128.16 (2CH of Ph), 128.43 (CH of Ph), 131.61 (CH of Ph), 139.50 (C_{ipso} of Ph), 139.73 (C_{ipso}–CO), 165.14 (C=CCH₃), 169.16 (C=CCOPh and CONH), 189.61 (COPh). MS, *m/z* (%): 432 (M⁺, 10), 361 (5), 332 (100), 254 (7), 228 (7), 105 (55), 77 (29), 57 (10), 42 (17).

Crystal data for **3b**: C₂₇H₃₂N₂O₃ (CCDC 656205); *M*_w=432.55, monoclinic, space group *P*2₁/*c*, *a*=13.5951(17) Å, *b*=9.7986(12) Å, *c*=18.906(2) Å, β =107.821(2)°, *V*=2397.7(5) Å³, *Z*=4, *D*_c=1.195 mg/m³, *F*(000)=928, crystal dimension 0.20×0.20×0.10 mm, radiation, Mo K α (λ =0.71073 Å), 2.61≤2 θ ≤25.09, intensity data were collected at 295(2) K with a Bruker APEX area-detector diffractometer, and

employing $\omega/2\theta$ scanning technique, in the range of $-16\leq h\leq 16$, $-11\leq k\leq 9$, $-22\leq l\leq 21$; the structure was solved by a direct method, all non-hydrogen atoms were positioned and anisotropic thermal parameters refined from 2340 observed reflections with *R*(int)=0.0416 by a full-matrix least-squares technique converged to *R*=0.0613 and *R*_w=0.1655 [*I*>2 σ (*I*)].

4.2.3. 5-Hydroxy-1-isobutyl-*N*³-isopropyl-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (3c)

Red crystals (0.41 g, 95%), mp 178–180 °C. Found: C, 74.86; H, 7.43; N, 6.33%; C₂₇H₃₂N₂O₃ requires C, 74.97; H, 7.46; N, 6.48%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3265 (OH), 3025 (NH), 1622 (COPh), 1580 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.77 (3H, d, ³*J*_{HH}=6.5 Hz, CH₃CHCH₂), 0.79 (3H, d, ³*J*_{HH}=6.6 Hz, CH₃CHCH₂), 1.24 (3H, d, ³*J*_{HH}=5.8 Hz, CH₃CH), 1.29 (3H, d, ³*J*_{HH}=5.8 Hz, CH₃CH), 1.84–1.86 (1H, m, CHCH₂), 2.43 (3H, s, CH₃), 2.90 (1H, dd, ²*J*_{HH}=14.4 Hz, ³*J*_{HH}=6.9 Hz, CHCH₂), 3.11 (1H, dd, ²*J*_{HH}=14.1 Hz, ³*J*_{HH}=7.3 Hz, CHCH₂), 4.30–4.31 (1H, m, CHNH), 5.55 (1H, s, NH), 6.75 (1H, s, C=CH), 7.23–7.71 (10H, 5CH of Ph), 9.39 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =14.27 (C=CCH₃), 20.19 (CH₂CHCH₃), 20.39 (CH₂CHCH₃), 23.13 (CH₃CHNH), 23.28 (CH₃CHNH), 28.26 (CHCH₂), 41.37 (CHNH), 50.16 (CH₂N), 97.13 (C–OH), 101.92 (C=CCONH), 106.72 (C=CCOPh), 125.75 (2CH of Ph), 127.81 (4CH of Ph), 127.89 (2CH of Ph), 128.25 (2CH of Ph), 128.44 (CH of Ph), 131.63 (CH of Ph), 139.61 (C_{ipso} of Ph), 139.83 (C_{ipso}–CO), 164.20 (C=CCH₃), 169.48 (C=CCOPh), 169.62 (CONH), 189.42 (COPh). MS, *m/z* (%): 432 (M⁺, 10), 375 (9), 346 (100), 290 (9), 242 (7), 105 (68), 77 (34), 57 (14), 41 (9).

4.2.4. 5-Hydroxy-*N*³-isobutyl-1-isopropyl-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (3d)

Orange crystals (0.38 g, 90%), mp 170–172 °C. Found: C, 74.86; H, 7.29; N, 6.53%; C₂₇H₃₂N₂O₃ requires C, 74.97; H, 7.46; N, 6.48%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3370 (OH), 3025 (NH), 1631 (COPh), 1580 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.85–0.89 (6H, m, Me₂CHCH₂), 0.95–1.02 (6H, m, Me₂CHN), 1.85–1.91 (1H, m, CH₂CH), 2.57 (3H, s, CH₃), 3.20–3.25 (1H, m, CH₂), 3.30–3.36 (1H, m, CH₂), 3.95–4.01 (1H, m, CHN), 5.74 (1H, s, NH), 6.66 (1H, s, C=CH), 7.21–7.71 (10H, 5CH of Ph), 9.63 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =15.10 (CH₃), 20.30 (Me₂CHCH₂NH), 21.37 (CH₃CHN), 22.26 (CH₃CHN), 28.72 (CHCH₂), 46.58 (CHN), 46.93 (CH₂NH), 97.29 (C–OH), 101.29 (C=CCONH), 107.22 (C=CCOPh), 125.77 (2CH of Ph), 127.72 (2CH of Ph), 127.80 (2CH of Ph), 128.12 (2CH of Ph), 128.34 (CH of Ph), 131.48 (CH of Ph), 139.12 (C_{ipso} of Ph), 139.86 (C_{ipso}–CO), 165.15 (C=CCH₃), 169.30 (C=CCOPh), 169.35 (HNCO), 189.42 (COPh). MS, *m/z* (%): 432 (M⁺, 15), 360 (9), 332 (97), 313 (34), 290 (14), 240 (15), 228 (37), 198 (24), 105 (100), 77 (49), 57 (6), 42 (20).

4.2.5. 5-Hydroxy-*N*³-1-diisobutyl-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (**3e**)

Orange crystals (0.40 g, 90%), mp 170–172 °C. Found: C, 75.23; H, 7.59; N, 6.17%; C₂₈H₃₄N₂O₃ requires C, 75.31; H, 7.67; N, 6.27%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3260 (OH), 3040 (NH), 1600 (COPh), 1550 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.77 (3H, d, ³*J*_{HH}=6.4 Hz, CH₃CHCH₂NH), 0.80 (3H, d, ³*J*_{HH}=6.4 Hz, CH₃CHCH₂NH), 1.00 (6H, d, ³*J*_{HH}=6.3 Hz, Me₂CH₂CHN), 1.82–1.91 (2H, m, 2CH), 2.44 (3H, s, CH₃), 2.91 (1H, dd, ²*J*_{HH}=14.4 Hz, ³*J*_{HH}=7.0 Hz, CH₂NH), 3.13 (1H, dd, ²*J*_{HH}=14.4 Hz, ³*J*_{HH}=7.4 Hz, CH₂NH), 3.23 (1H, dd, ²*J*_{HH}=12.5 Hz, ³*J*_{HH}=5.6 Hz, CH₂N), 3.32–3.35 (1H, m, CH₂N), 5.76 (1H, s, NH), 6.75 (1H, s, C=CH), 7.22–7.71 (10H, 5CH of Ph), 9.42 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =14.30 (CH₃), 20.13 (Me₂CHCH₂NH), 20.34 (Me₂CH₂CHN), 28.23 (CHCH₂NH), 28.72 (CHCH₂N), 46.95 (CH₂NH), 50.11 (CH₂N), 97.08 (C–OH), 102.07 (C=CCONH), 106.66 (C=CCOPh), 125.71 (2CH of Ph), 127.84 (4CH of Ph), 128.15 (2CH of Ph), 128.41 (CH of Ph), 131.59 (CH of Ph), 139.57 (C_{ipso} of Ph), 139.78 (C_{ipso}–CO), 165.15 (C=CCH₃), 169.43 (C=CCOPh), 169.79 (HNCO), 189.61 (COPh). MS, *m/z* (%): 446 (M⁺, 14), 374 (8), 346 (100), 327 (19), 254 (12), 242 (16), 105 (73), 77 (33), 57 (24), 41 (15).

4.2.6. 5-Hydroxy-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-*N*³-1-dipropyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (**3f**)

Orange crystals (0.35 g, 85%), mp 170–172 °C. Found: C, 74.59; H, 7.17; N, 6.73%; C₂₆H₃₀N₂O₃ requires C, 74.61; H, 7.22; N, 6.69%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3245 (OH), 3040 (NH), 1602 (COPh), 1558 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.75 (3H, br, CH₃CH₂CH₂NH), 1.00 (3H, br, CH₃CH₂CH₂N), 1.44–1.45 (2H, m, CH₃CH₂), 1.62–1.64 (2H, m, CH₃CH₂), 2.45 (3H, s, CH₃), 3.12 (1H, br, CH₂NH), 3.28 (1H, br, CH₂NH), 3.40–3.42 (1H, m, CH₂N), 5.72 (1H, s, NH), 6.75 (1H, s, C=CH), 7.25–7.72 (10H, 5CH of Ph), 9.38 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =11.35 (CH₃CH₂), 11.57 (CH₃CH₂), 13.76 (CH₃), 23.05 (CH₃CH₂), 23.16 (CH₃CH₂), 41.22 (CH₂NH), 44.07 (CH₂N), 96.53 (C–OH), 102.23 (C=CCONH), 106.30 (C=CCOPh), 125.61 (2CH of Ph), 127.85 (2CH of Ph), 127.88 (2CH of Ph), 128.18 (2CH of Ph), 128.42 (CH of Ph), 131.60 (CH of Ph), 139.54 (C_{ipso} of Ph), 139.77 (C_{ipso}–CO), 165.08 (C=CCH₃), 169.02 (C=CCOPh), 169.17 (HNCO), 189.63 (COPh). MS, *m/z* (%): 418 (M⁺, 14), 361 (4), 332 (100), 299 (10), 254 (9), 228 (9), 105 (52), 77 (30), 42 (19).

4.2.7. *N*³-(*tert*-Butyl)-5-hydroxy-1-isobutyl-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (**3g**)

Orange crystals (0.40 g, 90%), mp 165–167 °C. Found: C, 75.19; H, 7.81; N, 6.16%; C₂₈H₃₄N₂O₃ requires C, 75.31; H, 7.67; N, 6.27%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3305 (OH), 3030 (NH), 1636 (COPh), 1612 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.74–0.80 (6H, m, CH₃CH), 1.47 (9H, s,

Me₃C), 1.86 (1H, m, CH), 2.42 (3H, s, CH₃), 2.87–2.92 (1H, m, CH₂), 3.08–3.13 (1H, m, CH₂), 5.56 (1H, s, NH), 6.73 (1H, s, C=CH), 7.21–7.71 (10H, 5CH of Ph), 9.43 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =14.21 (CH₃), 20.14 (CH₃CH), 20.33 (CH₃CH), 28.21 (CH), 29.33 (Me₃C), 50.11 (CH₂), 51.51 (Me₃C), 97.08 (C–OH), 101.63 (C=CCONH), 107.72 (C=CCOPh), 125.71 (2CH of Ph), 127.70 (2CH of Ph), 127.84 (2CH of Ph), 128.21 (2CH of Ph), 128.37 (CH of Ph), 131.53 (CH of Ph), 139.54 (C_{ipso} of Ph), 139.87 (C_{ipso}–CO), 164.43 (C=CCH₃), 169.56 (C=CCOPh and CONH), 189.28 (COPh). MS, *m/z* (%): 446 (M⁺, 22), 374 (13), 347 (83), 327 (48), 271 (45), 242 (69), 228 (24), 198 (27), 105 (100), 77 (46), 57 (37), 41 (33).

4.2.8. *N*³-(*tert*-Butyl)-5-hydroxy-2-methyl-4-(2-oxo-2-phenylethylidene)-5-phenyl-1-propyl-4,5-dihydro-1*H*-pyrrol-3-carboxamide (**3h**)

Orange crystals (0.39 g, 90%), mp 172–174 °C. Found: C, 74.56; H, 7.63; N, 6.29%; C₂₇H₃₂N₂O₃ requires C, 74.97; H, 7.46; N, 6.48%. IR (KBr) ($\nu_{\max}$, cm⁻¹): 3295 (OH), 3025 (NH), 1638 (COPh), 1570 (CONH). ¹H NMR (500.1 MHz, CDCl₃): δ_{H} =0.76 (3H, t, ³*J*_{HH}=7.2 Hz, CH₃CH₂), 1.13 (1H, br, CH₃CH₂), 1.47 (9H, s, Me₃C), 2.43 (3H, s, CH₃), 3.07–3.30 (2H, m, CH₂N), 5.53 (1H, s, NH), 6.74 (1H, s, C=CH), 7.23–7.72 (10H, 5CH of Ph), 9.40 (1H, s, OH). ¹³C NMR (125.7 MHz, CDCl₃): δ_{C} =11.34 (CH₃CH₂), 13.71 (CH₃), 23.07 (CH₃CH₂), 29.34 (Me₃C), 44.07 (CH₂N), 51.49 (Me₃C), 96.56 (C–OH), 101.74 (C=CCONH), 107.38 (C=CCOPh), 125.63 (2CH of Ph), 127.72 (2CH of Ph), 127.88 (2CH of Ph), 128.22 (2CH of Ph), 128.39 (CH of Ph), 131.54 (CH of Ph), 139.49 (C_{ipso} of Ph), 139.84 (C_{ipso}–CO), 164.43 (C=CCH₃), 168.92 (C=CCOPh), 169.30 (CONH), 189.31 (COPh). MS, *m/z* (%): 432 (M⁺, 12), 346 (4), 332 (100), 314 (5), 290 (11), 254 (6), 105 (52), 77 (27), 57 (12), 42 (15).

Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.tet.2007.10.098.

References and notes

- (a) Patterson, J. M. *Synthesis* **1976**, 281–304; (b) Jones, R. A.; Bean, G. P. *The Chemistry of Pyrroles*; Academic: London, 1977; (c) Jones, G. B.; Chapman, B. J. *Comprehensive Heterocyclic Chemistry*; Bird, C. W., Ed.; Pergamon: Oxford, 1996; Vol. 2, pp 1–38; (d) Black, D. St. C. *Comprehensive Heterocyclic Chemistry*; Bird, C. W., Ed.; Pergamon: Oxford, 1996; Vol. 2, pp 39–118; (e) Sundberg, R. J. *Comprehensive Heterocyclic Chemistry*; Bird, C. W., Ed.; Pergamon: Oxford, 1996; Vol. 2, pp 119–206; (f) Gribble, G. W. *Comprehensive Heterocyclic Chemistry*; Bird, C. W., Ed.; Pergamon: Oxford, 1996; Vol. 2, pp 207–257.
- (a) Herbert, R. B. *The Alkaloid*; Grundon, M. F., Ed.; Chemical Society: London, 1982; Vol. 12; (b) Falk, H. *The Chemistry of Linear Oligopyrroles and Bile Pigments*; Springer: Berlin, 1989; (c) *Biosynthesis of Tetrapyrroles*; Jordan, P. M., Ed.; Elsevier: London, 1991.
- Porphyrins and Metalloporphyrins*; Smith, K. M., Ed.; Elsevier: Amsterdam, 1975; Franck, B.; Nonn, A. *Angew. Chem., Int. Ed. Engl.* **1995**, *34*, 1795–1811; Sessler, J. L.; Weghorn, S. J. *Expanded, Contracted and Isomeric Porphyrins*; Pergamon: Oxford, 1997.

4. Meanwell, N. A.; Romine, J. L.; Rosenfeld, M. J.; Martin, S. W.; Trehan, A. K.; Wright, J. J. K.; Malley, M. F.; Gougoutas, J. Z.; Brassard, C. L.; Buchanan, J. O.; Federici, M. E.; Fleming, J. S.; Gamberdella, M.; Hartl, K. S.; Zavoico, G. B.; Seiler, S. M. *J. Med. Chem.* **1993**, *36*, 3884–3903.
5. (a) Holland, G. F. U.S. Patent 4,282,242, 1981; *Chem. Abstr.* **1981**, *95*, 187068e; (b) Nippon Soda Co., Ltd. Japanese Patent 81 79,672, 1981; *Chem. Abstr.* **1981**, *95*, 187069f; (c) Umio, S.; Kariyone, K. Japanese Patent 68 14,699, 1968; *Chem. Abstr.* **1969**, *70*, 87560z.
6. Anderson, H. J.; Loader, C. E.; Xu, R. X.; Lê, N.; Gogan, N. J.; McDonald, R.; Edwards, L. G. *Can. J. Chem.* **1985**, *63*, 896–902.
7. (a) Gabel, N. W. *J. Org. Chem.* **1962**, *27*, 301–303; (b) van Leusen, A. M.; Siderius, H.; Hoogenboom, B. E.; van Leusen, D. *Tetrahedron Lett.* **1972**, 5337–5340; (c) Groves, J. K.; Cundasawmy, N. E.; Anderson, H. J. *Can. J. Chem.* **1973**, *51*, 1089–1098; (d) Ichimura, K.; Ichikawa, S.; Iwamura, K. *Bull. Chem. Soc. Jpn.* **1976**, *49*, 1157–1158; (e) van Nispen, S. P. J. M.; Mensink, C.; van Leusen, A. M. *Tetrahedron Lett.* **1980**, *21*, 3723–3726; (f) Muchowski, J. M.; Naef, R. *Helv. Chim. Acta.* **1984**, *67*, 1168–1172; (g) Magnus, P.; Danikiewicz, W.; Katoh, T.; Huffman, J. C.; Folting, K. *J. Am. Chem. Soc.* **1990**, *112*, 2465–2468; (h) Shum, P. W.; Kozikowski, A. P. *Tetrahedron Lett.* **1990**, *31*, 6785–6788; (i) Alvarez, A.; Guzmán, A.; Ruiz, A.; Velarde, E.; Muchowski, J. M. *J. Org. Chem.* **1992**, *57*, 1653–1656; (j) van Leusen, D.; van Echten, E.; van Leusen, A. M. *J. Org. Chem.* **1992**, *57*, 2245–2249; (k) Ho-Hoang, A.; Fache, F.; Lemaire, M. *New J. Chem.* **1992**, *16*, 1017–1018; (l) Seino, H.; Ishii, Y.; Hidai, M. *J. Am. Chem. Soc.* **1994**, *116*, 7433–7434; (m) Cooper, J. M.; Morris, D. G.; Ryder, K. S. *J. Chem. Soc., Chem. Commun.* **1995**, 697–698; (n) Sugihara, Y.; Miyatake, R.; Murata, I.; Imamura, A. *J. Chem. Soc., Chem. Commun.* **1995**, 1249–1250; (o) Seino, H.; Ishii, Y.; Sasagawa, T.; Hidai, M. *J. Am. Chem. Soc.* **1995**, *117*, 12181–12193; (p) Head, N. E.; Turner, J. J. *J. Org. Chem.* **1995**, *60*, 4302–4304; (q) ten Have, R.; Leusink, F. R.; van Leusen, A. M. *Synthesis* **1996**, 871–876; (r) Pavri, N. P.; Trudell, M. L. *J. Org. Chem.* **1997**, *62*, 2649–2651; (s) Scheffer, J. R.; Ihmels, H. *Liebigs Ann.* **1997**, 1925–1929; (t) Merz, A.; Meyer, T. *Synthesis* **1999**, 94–99; (u) Zelikin, A.; Shastri, V. R.; Lange, R. *J. Org. Chem.* **1999**, *64*, 3379–3380; (v) Donohoe, T. J.; Harji, R. R.; Cousins, R. P. C. *Chem. Commun.* **1999**, 141–142; (w) Shiraishi, H.; Nishitani, T.; Nishihara, T.; Sakaguchi, S.; Ishii, Y. *Tetrahedron* **1999**, *55*, 13957–13964.
8. Alizadeh, A.; Movahedi, F.; Esmaili, A. A. *Tetrahedron Lett.* **2006**, *47*, 4469–4471.
9. Alizadeh, A.; Movahedi, F.; Masrour, H.; Zhu, L. G. *Synthesis* **2006**, *20*, 3431–3436.
10. Alizadeh, A.; Zohreh, N.; Rostamnia, S. *Tetrahedron* **2007**, *63*, 8083–8087.
11. Gao, Y.; Shirai, M.; Sato, F. *Tetrahedron Lett.* **1997**, *38*, 6849–6852.
12. Skattebol, L.; Jones, E. R. H.; Whiting, M. C. *Organic Synthesis Collective Vol. IV*; Wiley: New York, NY, 1963; p 792.
13. Bowden, K.; Heilbron, I. M.; Jones, E. R. H.; Weedon, B. C. *J. Chem. Soc.* **1946**, 39–45.